The 20 Largest Medical Device Companies In the World

Share

Boston ScientificNo. 13: Boston Scientific

Marlborough, Mass.

www.bostonscientific.com

2016 RANK: 16

Revenue: $8,386,000,000

Fiscal year ending: Dec. 31, 2016

Employees: 27,000

R&D Spend: $920,000,000

Key Personnel:

Michael Mahoney, chairman & CEO; Kevin Ballinger, EVP & president, interventional cardiology; Supratim Bose, EVP & president, Asia-Pacific, Middle East & Africa; Daniel Brennan, EVP & CFO; Art Butcher, SVP & president, endoscopy; Wendy Carruthers, SVP, HR; Joseph Fitzgerald, EVP & president, rhythm management; Edward Mackey, EVP, global operations; Dr. Ian Meredith, EVP & global CMO; Jeff Mirviss, SVP & president, peripheral interventions; Maulik Nanavaty, SVP & president, neuromodulation; Michael Phalen, EVP & president, medsurg; David Pierce, SVP & health; Timothy Pratt, EVP, chief administrative officer, general counsel & secretary; Brad Sorenson, SVP, manufacturing & supply chain; Eric Thépaut, SVP & president, Europe

Description:

Boston Scientific put its turnaround in the rear view mirror in 2016 and set its sights on accelerating and stabilizing that growth by expanding into high-growth adjacent markets.

“Our investment strategy has focused on diversifying our portfolio and shifting the growth profile of the company toward higher-growth markets and focusing on globalization,” a company spokeswoman told us, noting that once-core products likes stents, pacemakers and defibrillators are now only 50% of the total offering.

“We expect that to be about a third as we continue to grow with our robust pipeline,” she said, adding that nearly half of Boston Scientific’s sales come from global markets.

A June 2016 restructuring meant little net change to total employment numbers, as BSC looked to pare its pre-tax expenses by $115 million to $150 million by the end of 2020.

Download the full Big 100 list here.

And you can also pick up a free hard copy of the Big 100 issue at DeviceTalks Boston on Oct. 2!

Next>>

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Pages: 1 2 3 4 5 6 7 8 9 10 11

Comments

  1. Chris Newmarker says:

    Apologies. We had to fix a technical glitch with the Big 100 spreadsheet download. If you fill out the sign-up form now, you should get an email with a link to download the spreadsheet, instead of last year’s Big 100 edition.

  2. Chris, Thank you for the update. I just downloaded the Big 100.

Speak Your Mind

*